Photos - Pharma Japan -

Sunday, April.22.2018

Remember Me

Home＞Photo


PhRMA Chief Warns of Serious Implications for Japan Market after 2018 Pricing Reform (Apr.13)		MHLW Panel Starts Discussions on PMD Law Amendment; Will First Verify Results of Previous Amendment (Apr.12)		Chuikyo Payer Rep Questions New Premium System for Cost-Based Pricing Method (Apr.12)


MOF Calls for Using CEA to Make Reimbursement Decisions for Pricy Drugs (Apr.12)		Company Category Criteria for Price Maintenance Premium Tough on Ophthalmic Drug Makers: Industry Group (Apr.09)		Alfresa to Fully Introduce Distribution Cost Analysis System; Will “Raise Reps’ Awareness of Importance of Price Negotiations”: Pres. (Apr.09)


MHLW to Discuss Stockpiling of Xofluza, Tamiflu Generics in FY2018 (Apr.03)		Lynparza Desirable for Use in Early-Stage Maintenance Therapy: Jikei Univ. Prof. (Apr.02)		Chuikyo Begins Debate on Sales Tax Hike, Agrees on Drug Price Survey in 2018 (Apr.02)


Bayer Gives Update on Initiatives after Xarelto Survey Scandal (Mar.30)		Alliance with Nichi-Iko “Not Due to Pessimism about Generic Drug Business,” Will Expand Lineup: Eisai CEO (Mar.30)		Fujifilm to Gobble Up 2 Cell Culture Media Firms for US$800 million (Mar.30)

＜ Prev 1 2 3 4 5 6 7 8 9 10 Next ＞

With Drug Price Cuts Done, MHLW Now Running Ministry-Wide Initiative to Shave Prescriptions

G1/G2 Rule：
G1/G2ルール

It Is Thumbs Up for Cell Therapy in Japan

No Dialogue at New “Public-Private Dialogue” Confab with Limited Time, JPMA Says(Apr.20)

Expert Cautions against Hasty Discussions on Cost Effective Assessments(Apr.20)

Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR(Apr.20)

Takeda in Talks with Shire after 3 Buyout Proposals Rejected(Apr.20)

Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers(Apr.20)

1.: AZ’s PD-L1 Inhibitor Durvalumab Up for M...
2.: Tecentriq Now in PD-1/L1 NSCLC Showdown,...
3.: Tecentriq to Provide New Option for NSCL...
4.: PhRMA Chief Warns of Serious Implication...
5.: Pharma Leaders Air Grievances on Pricing...